#Hong Kong #ADC #BioNTech #DualityBio

DualityBio Announces 2025 Annual Results

On March 24, 2026, Duality Biotherapeutics Inc. (9606.HK) revealed its first yearly financial performance since its initial public offering, marking a pivotal point in its journey. Operating as an innovative biopharmaceutical entity, DualityBio has made significant advancements in its clinical pipeline and corporate strategy, aiming to tackle challenging diseases worldwide.

Leadership Insights

Dr. John Zhu, the visionary founder and CEO of DualityBio, elaborated on the transformative landscape of the pharmaceutical industry. He noted the transition from fragmented exploration to a more cohesive, global approach, emphasizing a collective effort towards innovation. "Today, we embrace an era of possibilities that transcends regional boundaries; our systems of clinical testing and regulatory frameworks are converging. Innovation now arises from seamless global collaborations,” stated Dr. Zhu.

In 2025, DualityBio focused on its Antibody-Drug Conjugate (ADC) initiatives, capitalizing on its advanced technology framework to expedite the development of its key assets. With over 3,200 patients enrolled across clinical trials, the company has demonstrated robust research and development capabilities.

Financial Highlights

In terms of finances, DualityBio reported a revenue of RMB 1.852 billion, establishing a strong fiscal base for continued growth. Its research and development expenditures stood at RMB 838 million, underscoring the company's commitment to innovation. The adjusted loss was recorded at RMB 389 million, a figure reflecting the fair value adjustment of prior capital raises, as the company transitioned to its current public structure. Critically, DualityBio maintained a healthy cash position of RMB 3.325 billion as of the reporting period's end, bolstered by consistent positive cash flow from operations for three years.

Clinical Momentum

2025 saw the accelerated progress of the ADC pipeline, with ten clinical-stage ADC candidates currently in development. Noteworthy achievements included the significant advancements in the clinical trial for Trastuzumab pamirtecan (DB-1303), with findings affirming its efficacy in treating HER2-positive breast cancer. Moreover, the submission of a Biologics License Application to regulatory bodies signifies the company's proactive approach in getting its products to market.

Complementary to this is the promising progress in the DB-1311/BNT324 ADC candidate, as revealed through data presented at various oncology symposiums. These updates highlighted promising survival rates for patients with metastatic prostate cancer and displayed its potential in treating gynecological tumors, marking continuous progress in the company’s therapeutic offerings.

Strategic Collaborations

DualityBio's strategic expansion is mirrored through its robust collaboration network, which includes key industry players such as BioNTech and Avenzo. This collaboration aims to magnify the potential of its innovative therapies through shared resources and strategic insights. The company envisions leveraging Bispecific Antibodies partnered with ADC platforms to explore novel treatment avenues in oncology.

Future Projections

Looking ahead into 2026, DualityBio plans to escalate its product commercialization efforts while enhancing its research capabilities. This involves targeting the A-share listing and continuous engagement with international markets to ensure sustained innovation and patient care solutions globally. The company remains committed to aligning its research goals with pressing clinical needs and is poised to lead with diverse offerings tailored for patients battling complex diseases.

In its journey, DualityBio aims to not only expand its product lines but also fortify its presence as a key player in the global biopharmaceutical arena, delivering on the promise of innovation to meet the challenges of today’s health landscape.

Conclusion

As DualityBio continues to carve its path in the biopharmaceutical sector, its foundational principles of innovation, collaboration, and context-driven strategies remain instrumental. With a strong focus on transformative therapies and a commitment to overcoming healthcare challenges, DualityBio is set for a future filled with possibilities.